BBI Solutions is gearing up to attend MEDLAB Middle East in Dubai next month.
BBI Solutions (BBI), a leading and rapidly expanding manufacturer of raw materials and finished test platforms for the in-vitro diagnostics market, is gearing up to attend MEDLAB Middle East in Dubai next month.
The world’s largest laboratory exhibition is being held in the Dubai International Convention Centre on the 5th-8th February. MEDLAB will provide the perfect backdrop for BBI to showcase its expanded offering of over 80 new antibodies and custom antibody development and production services following, the recent acquisition of Maine Biotechnology Services (MBS).
BBI already provides human antigens, antibodies, serum and plasma products and clinical chemistry enzymes, for the in-vitro diagnostics market. The acquisition of MBS brings 27 years of experience in hybridoma and assay development and strengthens BBI’s antibody offering, providing a comprehensive portfolio and custom antibody development services to deliver a total reagent solution for any immunoassay development.
Dr. James Steggles, BBI’s Commercial Manager for Antibodies, said “the acquisition of MBS gives us an opportunity to significantly grow our portfolio of antibodies to a wide variety of targets, while still maintaining the performance and quality standards our customers expect from us.
“We are also very pleased to now have in-house hybridoma development capabilities that will allow us to continue growing our offering with novel antibodies, directly in response to customer needs,” continued James.
The delegation at MEDLAB will also be showcasing BBI’s brand new global headquarters in Wales, UK. The £14 million investment into the development of this new site is part of ambitious plans to create a world-class facility. The new site brings together three of its existing UK manufacturing locations into one. It will provide capacity for customers’ growing businesses and keeps BBI ahead of the regulatory changes that are being driven through the market. It also consolidates an experienced workforce under one roof to collaborate in delivering the best result for customer’s tests.
You can speak first hand with the BBI team on stand Z5 G44 at MEDLAB Middle East. They will be available to discuss BBI’s recent expansion, complete reagents portfolio and assay development services. You can also learn about the 80 new industry leading antibodies available through BBI, as well as, how BBI’s custom antibody development service can provide you with the reagents you are specifically looking for. Meetings can be pre-booked to guarantee a dedicated time slot with the BBI team, visit www.bbisolutions.com.
About
BBI Solutions is a leading supplier of biological raw materials and finished test platforms to the in-vitro diagnostic market. We have grown from a small specialist company to a global business with manufacturing sites spanning three continents.
We deliver exceptional products and services that people ultimately rely on to enjoy a better quality of life.
Our range of raw materials includes antigens, antibodies, enzymes and serum and plasma products. We manufacture world renowned labels for lateral flow and ELISA, including our gold nanoparticles, horseradish peroxidase and alkaline phosphatase. Our glucose oxidase is used in over 5 billion blood glucose monitoring test strips every year.
We offer end to end outsourced development and manufacturing services across a number of lateral flow and related platforms. Over 30 years, we have successfully completed more than 250 projects. Using the latest technologies and platforms, customers have come to rely on BBI to deliver next generation assay performance.
BBI Solutions is part of the BBI Group.
www.bbisolutions.com
Media Contact
Laura Baker
Phone: +44 (0) 2920 747 232
Email: laurabaker@bbisolutions.com
